A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor Bispecific Antibody, as First- or Second-Line Therapy for Advanced or Metastatic Immunotherapy-Naive NSCLC

医学 二线疗法 内科学 血管内皮生长因子 抗体疗法 双特异性抗体 抗体 肿瘤科 免疫疗法 癌症研究 癌症 免疫学 化疗 血管内皮生长因子受体 单克隆抗体
作者
Lei Wang,Yongzhong Luo,Shengxiang Ren,Zhihong Zhang,Anwen Xiong,Chunxia Su,Jin Zhou,Xinmin Yu,Yanping Hu,Xiaodong Zhang,Xiaorong Dong,Shuyan Meng,Fengying Wu,Xiaoming Hou,Yuanrong Dai,Weifeng Song,Baiyong Li,Zhongmin Maxwell Wang,Xia Yu,Caicun Zhou
出处
期刊:Journal of Thoracic Oncology [Elsevier BV]
卷期号:19 (3): 465-475 被引量:60
标识
DOI:10.1016/j.jtho.2023.10.014
摘要

PURPOSE This study aimed to evaluate the safety and efficacy of ivonescimab (a bispecific antibody against programmed death-1 [PD-1] and vascular endothelial growth factor [VEGF]) as first- or second-line monotherapy in advanced immunotherapy naïve non-small-cell lung cancer (NSCLC) patients. METHODS Eligible patients received intravenous ivonescimab 10mg/kg every 3 weeks (Q3W), 20 mg/kg every 2 weeks (Q2W), 20 mg/kg Q3W or 30mg/kg Q3W. The primary endpoints were safety and objective response rate (ORR) per RECIST v1.1. RESULTS At data cutoff (October 5, 2022), 108 patients were enrolled and received ivonescimab. Programmed death ligand-1 (PD-L1) tumor proportion score (TPS) was ≥1% in 74 (68.5%) patients, including 35 (32.4%) with TPS ≥50%. The median follow-up was 10.4 months (range 8.4 to 10.9 months). For all patients, ORR and disease control rate (DCR) were 39.8% and 86.1%, respectively. ORR by TPS was 14.7%, 51.4% and 57.1% in patients with TPS <1%, ≥1%, and ≥50%, respectively. In the 67 PD-L1 positive patients receiving first-line ivonescimab, the ORR was 33.3%, 52.6%, 60.0%, and 75.0% at the doses of 10mg/kg Q3W, 20 mg/kg Q2W, 20 mg/kg Q3W and 30mg/kg Q3W, respectively. Grade ≥3 treatment-related adverse events (TRAEs) were observed in 24 (22.2%) patients. TRAEs leading to treatment discontinuation occurred in 1 (0.9%) patient. TRAEs leading to death occurred in 3 (2.8%) patients with squamous histology. The occurrence of grade ≥3 TRAEs and grade ≥3 bleeding events in squamous versus non-squamous histologies were 25.5% vs. 18.9% and 0.0% vs. 1.9%, respectively. CONCLUSION Ivonescimab monotherapy was well tolerated and demonstrated promising efficacy in patients with advanced or metastatic NSCLC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
JUZI完成签到,获得积分10
1秒前
怀石逾沙发布了新的文献求助10
1秒前
大钟完成签到 ,获得积分20
2秒前
2秒前
科研通AI6.2的应助被tangtang采纳,获得10
2秒前
共享精神的应助被张昌国采纳,获得10
2秒前
星辰大海的应助被科研通管家采纳,获得10
2秒前
2秒前
swsx1317完成签到,获得积分10
2秒前
2秒前
共享精神的应助被科研通管家采纳,获得10
2秒前
wk123完成签到 ,获得积分20
3秒前
3秒前
3秒前
holoka发布了新的文献求助10
3秒前
azz完成签到 ,获得积分10
3秒前
3秒前
小惠完成签到,获得积分10
4秒前
4秒前
暴躁的水蜜桃完成签到 ,获得积分10
4秒前
大胆的乐荷完成签到,获得积分10
4秒前
流氓兔完成签到 ,获得积分10
5秒前
5秒前
淡然胡萝卜完成签到,获得积分10
5秒前
断了的弦完成签到,获得积分10
6秒前
刚刚好完成签到,获得积分10
6秒前
ZXW完成签到,获得积分10
6秒前
认真的纸鹤完成签到 ,获得积分10
7秒前
lalala完成签到,获得积分10
7秒前
yeer发布了新的文献求助10
7秒前
研友_LBorkn完成签到,获得积分10
7秒前
8秒前
大大彬完成签到 ,获得积分10
8秒前
窗外的天气完成签到,获得积分10
8秒前
拼搏太英完成签到,获得积分10
8秒前
明天更好发布了新的文献求助10
8秒前
渴望成功的学术残废完成签到,获得积分10
9秒前
ziy完成签到,获得积分10
9秒前
微子完成签到,获得积分10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8159212
求助须知:如何正确求助?哪些是违规求助? 9554678
关于积分的说明 21720538
捐赠科研通 7748887
什么是DOI,文献DOI怎么找? 3427184
关于科研通互助平台的介绍 2552092
邀请新用户注册赠送积分活动 2471464